Panel to Examine the Ongoing Evolution of Antibody Drug Conjugates in the Treatment of Breast Cancer
Antibody drug conjugates (ADCs), which use a targeted monoclonal antibody to deliver a cytotoxic payload, are among the most effective breast cancer therapies yet developed. The first Food and Drug Administration approval of an ADC in breast cancer, ado-trastuzumab emtansine, better known as T-DM1, sparked development of numerous new and promising ADCs for breast cancer.Source: SABCS Meeting News
Kirstie Alley and Colon Cancer: The Early Signs You Shouldn't Ignore
Actor Kirstie Alley has died after being diagnosed with colon cancer earlier this year. Colon cancer, also known as colorectal cancer, is the third most common type of cancer in the United States and globally. In the U.S. over 151,000 people will develop the disease in 2022.Source: Healthline
Spatial and Single Cell Characterization of Breast Cancer Progression: Presenter Profile
Presentation is about methods for assessment of multiple molecular variables on a single piece of tissue to better understand breast cancer (or really any cancer) with respect to progression or response or resistance to specific therapies.Source: SABCS Meeting News
Trastuzumab Deruxtecan Generates OS Benefit Vs Capecitabine-based Regimens in Pretreated HER2+ Breast Cancer
Trastuzumab deruxtecan demonstrated a 34% reduction in the risk of death and a 13-month increase in overall survival compared with treatment of physician’s choice in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who received prior treatment with trastuzumab emtansine.Source: OncLive
Where Are All the Women in Industry Advisory Boards?
A new study, co-authored by WHRY-collaborator Dr. Pamela Kunz, finds women are underrepresented in critical spaces of medicine, including academic and medical society leadership, journal editorial boards, and research teams. The authors suggest this absence may be holding women back in their careers.Source: Journal of Clinical Oncology
Why Some Lung Tumors Respond Better to Targeted Therapies Than Others
In a new study, Yale Cancer Center researchers found molecular explanations for why some lung tumors respond better to certain drugs than others. The research should help improve drug selection for lung cancer patients with different mutations in the EGF receptor, using a precision medicine approach to treatment.
Women Missing Out on Opportunities From Advisory Boards
Being on an advisory board of a pharmaceutical company gives oncologists a chance to influence clinical trials and drug commercialization and to "inform decisions that affect the oncology community," say the authors of a new analysis, which found few women in such roles.Source: Medscape
Barbara Burtness, MD, Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital
Barbara Burtness, MD, Professor of Medicine (Medical Oncology), has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.
Berzosertib Plus Standard Chemoradiation Elicits Promising Responses in Locally Advanced HNSCC
Aarti Bhatia, MD, discusses the rationale for investigating berzosertib in this patient population, key updates from the phase 1 trial, and how these findings support the need for continued research of novel regimens in HNSCC.Source: OncLive
Career Path: Women in Leadership at High Levels
Reaching high-level leadership positions in medicine—and specifically oncology—is not an easy task and requires significant time and dedication. For women, there are a host of additional challenges to contend with as they navigate their career.Source: Oncology Times